Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 104

1.

Direct Versus Calculated LDL Cholesterol and C-Reactive Protein in Cardiovascular Disease Risk Assessment in the Framingham Offspring Study.

Ikezaki H, Fisher VA, Lim E, Ai M, Liu CT, Adrienne Cupples L, Nakajima K, Asztalos BF, Furusyo N, Schaefer EJ.

Clin Chem. 2019 Sep;65(9):1102-1114. doi: 10.1373/clinchem.2019.304600. Epub 2019 Jun 25.

PMID:
31239251
2.

High-density lipoprotein: our elusive friend.

Asztalos BF, Niisuke K, Horvath KV.

Curr Opin Lipidol. 2019 Aug;30(4):314-319. doi: 10.1097/MOL.0000000000000612.

PMID:
31145119
3.

Effects of weight change on HDL-cholesterol and its subfractions in over 28,000 men and women.

Dansinger M, Williams PT, Superko HR, Asztalos BF, Schaefer EJ.

J Clin Lipidol. 2019 Mar - Apr;13(2):308-316. doi: 10.1016/j.jacl.2018.12.001. Epub 2018 Dec 18.

PMID:
30665769
4.

Genetic and secondary causes of severe HDL deficiency and cardiovascular disease.

Geller AS, Polisecki EY, Diffenderfer MR, Asztalos BF, Karathanasis SK, Hegele RA, Schaefer EJ.

J Lipid Res. 2018 Dec;59(12):2421-2435. doi: 10.1194/jlr.M088203. Epub 2018 Oct 17.

PMID:
30333156
5.

High-Density Lipoprotein Particles, Cell-Cholesterol Efflux, and Coronary Heart Disease Risk.

Asztalos BF, Horvath KV, Schaefer EJ.

Arterioscler Thromb Vasc Biol. 2018 Sep;38(9):2007-2015. doi: 10.1161/ATVBAHA.118.311117.

6.

Where next with HDL assays?

Niisuke K, Horvath KV, Asztalos BF.

Curr Opin Lipidol. 2018 Aug;29(4):293-298. doi: 10.1097/MOL.0000000000000529.

PMID:
29846266
7.

HDL Particle Measurement: Comparison of 5 Methods.

Matera R, Horvath KV, Nair H, Schaefer EJ, Asztalos BF.

Clin Chem. 2018 Mar;64(3):492-500. doi: 10.1373/clinchem.2017.277632. Epub 2017 Dec 4.

8.

Cardiovascular disease prevalence and insulin resistance in the Kyushu-Okinawa Population Study and the Framingham Offspring Study.

Ikezaki H, Ai M, Schaefer EJ, Otokozawa S, Asztalos BF, Nakajima K, Zhou Y, Liu CT, Jacques PF, Cupples LA, Furusyo N.

J Clin Lipidol. 2017 Mar - Apr;11(2):348-356. doi: 10.1016/j.jacl.2017.01.014. Epub 2017 Feb 3.

PMID:
28502490
9.

Influence of HDL particles on cell-cholesterol efflux under various pathological conditions.

Asztalos BF, Horvath KV, Mehan M, Yokota Y, Schaefer EJ.

J Lipid Res. 2017 Jun;58(6):1238-1246. doi: 10.1194/jlr.M075648. Epub 2017 Apr 18.

10.

Ethnic Differences in Glucose Homeostasis Markers between the Kyushu-Okinawa Population Study and the Framingham Offspring Study.

Ikezaki H, Ai M, Schaefer EJ, Otokozawa S, Asztalos BF, Nakajima K, Zhou Y, Liu CT, Jacques PF, Cupples LA, Furusyo N.

Sci Rep. 2016 Nov 10;6:36725. doi: 10.1038/srep36725.

11.

Effects of eicosapentaenoic acid and docosahexaenoic acid on cardiovascular disease risk factors: a randomized clinical trial.

Asztalos IB, Gleason JA, Sever S, Gedik R, Asztalos BF, Horvath KV, Dansinger ML, Lamon-Fava S, Schaefer EJ.

Metabolism. 2016 Nov;65(11):1636-1645. doi: 10.1016/j.metabol.2016.07.010. Epub 2016 Aug 26.

PMID:
27733252
12.

Comparing fluorescence-based cell-free assays for the assessment of antioxidative capacity of high-density lipoproteins.

Tsunoda F, Lamon-Fava S, Horvath KV, Schaefer EJ, Asztalos BF.

Lipids Health Dis. 2016 Sep 22;15(1):163.

13.

High-density lipoprotein subpopulation profiles in lipoprotein lipase and hepatic lipase deficiency.

Tani M, Horvath KV, Lamarche B, Couture P, Burnett JR, Schaefer EJ, Asztalos BF.

Atherosclerosis. 2016 Oct;253:7-14. doi: 10.1016/j.atherosclerosis.2016.08.014. Epub 2016 Aug 20.

14.

Diagnosis and treatment of high density lipoprotein deficiency.

Schaefer EJ, Anthanont P, Diffenderfer MR, Polisecki E, Asztalos BF.

Prog Cardiovasc Dis. 2016 Sep - Oct;59(2):97-106. doi: 10.1016/j.pcad.2016.08.006. Epub 2016 Aug 24. Review.

15.

High-Density Lipoprotein Subfractions and Cholesterol Efflux Capacities After Infusion of MDCO-216 (Apolipoprotein A-IMilano/Palmitoyl-Oleoyl-Phosphatidylcholine) in Healthy Volunteers and Stable Coronary Artery Disease Patients.

Kempen HJ, Asztalos BF, Moerland M, Jeyarajah E, Otvos J, Kallend DG, Bellibas SE, Wijngaard PL.

Arterioscler Thromb Vasc Biol. 2016 Apr;36(4):736-42. doi: 10.1161/ATVBAHA.115.307052. Epub 2016 Feb 25.

PMID:
26916733
16.

Fenofibrate, HDL, and cardiovascular disease in Type-2 diabetes: The DAIS trial.

Tsunoda F, Asztalos IB, Horvath KV, Steiner G, Schaefer EJ, Asztalos BF.

Atherosclerosis. 2016 Apr;247:35-39. doi: 10.1016/j.atherosclerosis.2016.01.028. Epub 2016 Jan 22.

17.

Identification and metabolic profiling of patients with lysosomal acid lipase deficiency.

Pullinger CR, Stock EO, Movsesyan I, Malloy MJ, Frost PH, Tripuraneni R, Quinn AG, Ishida BY, Schaefer EJ, Asztalos BF, Kane JP.

J Clin Lipidol. 2015 Sep-Oct;9(5):716-26.e1. doi: 10.1016/j.jacl.2015.07.008. Epub 2015 Jul 26.

PMID:
26350820
18.

Effect of almond consumption on vascular function in patients with coronary artery disease: a randomized, controlled, cross-over trial.

Chen CY, Holbrook M, Duess MA, Dohadwala MM, Hamburg NM, Asztalos BF, Milbury PE, Blumberg JB, Vita JA.

Nutr J. 2015 Jun 17;14:61. doi: 10.1186/s12937-015-0049-5.

19.

Effects of oral eicosapentaenoic acid versus docosahexaenoic acid on human peripheral blood mononuclear cell gene expression.

Tsunoda F, Lamon-Fava S, Asztalos BF, Iyer LK, Richardson K, Schaefer EJ.

Atherosclerosis. 2015 Aug;241(2):400-8. doi: 10.1016/j.atherosclerosis.2015.05.015. Epub 2015 May 19.

PMID:
26074314
20.

Case report: A novel apolipoprotein A-I missense mutation apoA-I (Arg149Ser)Boston associated with decreased lecithin-cholesterol acyltransferase activation and cellular cholesterol efflux.

Anthanont P, Asztalos BF, Polisecki E, Zachariah B, Schaefer EJ.

J Clin Lipidol. 2015 May-Jun;9(3):390-5. doi: 10.1016/j.jacl.2015.02.005. Epub 2015 Mar 5.

PMID:
26073399
21.

Cardiovascular Disease-Risk Markers in HIV Patients.

Asztalos BF, Matera R, Horvath KV, Horan M, Tani M, Polak JF, Skinner S, Wanke CA.

J AIDS Clin Res. 2014 Jun 12;5(7). pii: 317.

22.

Rosuvastatin Enhances the Catabolism of LDL apoB-100 in Subjects with Combined Hyperlipidemia in a Dose Dependent Manner.

Le NA, Diffenderfer MR, Thongtang N, Ooi EM, Barrett PH, Horvath KV, Dolnikowski GG, Asztalos BF, Schaefer EJ, Brown WV.

Lipids. 2015 May;50(5):447-58. doi: 10.1007/s11745-015-4005-0. Epub 2015 Mar 26.

PMID:
25809021
23.

Incubation of MDCO-216 (ApoA-IMilano/POPC) with Human Serum Potentiates ABCA1-Mediated Cholesterol Efflux Capacity, Generates New Prebeta-1 HDL, and Causes an Increase in HDL Size.

Kempen HJ, Schranz DB, Asztalos BF, Otvos J, Jeyarajah E, Drazul-Schrader D, Collins HL, Adelman SJ, Wijngaard PL.

J Lipids. 2014;2014:923903. doi: 10.1155/2014/923903. Epub 2014 Nov 12.

24.

Obesity associated molecular forms of C-reactive protein in human.

Asztalos BF, Horan MS, Horvath KV, McDermott AY, Chalasani NP, Schaefer EJ.

PLoS One. 2014 Oct 9;9(10):e109238. doi: 10.1371/journal.pone.0109238. eCollection 2014.

25.

Markers of Systemic Inflammation and Apo-AI Containing HDL Subpopulations in Women with and without Diabetes.

Russo GT, Giandalia A, Romeo EL, Alibrandi A, Horvath KV, Asztalos BF, Cucinotta D.

Int J Endocrinol. 2014;2014:607924. doi: 10.1155/2014/607924. Epub 2014 Sep 2.

26.

Effects of the absence of apolipoprotein e on lipoproteins, neurocognitive function, and retinal function.

Mak AC, Pullinger CR, Tang LF, Wong JS, Deo RC, Schwarz JM, Gugliucci A, Movsesyan I, Ishida BY, Chu C, Poon A, Kim P, Stock EO, Schaefer EJ, Asztalos BF, Castellano JM, Wyss-Coray T, Duncan JL, Miller BL, Kane JP, Kwok PY, Malloy MJ.

JAMA Neurol. 2014 Oct;71(10):1228-36. doi: 10.1001/jamaneurol.2014.2011.

27.

Short communication: effects of omega-3 fatty acids on triglycerides and high-density lipoprotein subprofiles in HIV-infected persons with hypertriglyceridemia.

Paranandi A, Asztalos BF, Mangili A, Kuvin J, Gerrior J, Sheehan H, Skinner SC, Tang AM, Wanke CA.

AIDS Res Hum Retroviruses. 2014 Aug;30(8):800-5. doi: 10.1089/AID.2014.0005.

28.

A novel ApoA-I truncation (ApoA-IMytilene) associated with decreased ApoA-I production.

Anthanont P, Polisecki E, Asztalos BF, Diffenderfer MR, Barrett PH, Millar JS, Billheimer J, Cuchel M, Rader DJ, Schaefer EJ.

Atherosclerosis. 2014 Aug;235(2):470-6. doi: 10.1016/j.atherosclerosis.2014.05.935. Epub 2014 Jun 2.

PMID:
24950002
29.

High-density lipoprotein metabolism, composition, function, and deficiency.

Schaefer EJ, Anthanont P, Asztalos BF.

Curr Opin Lipidol. 2014 Jun;25(3):194-9. doi: 10.1097/MOL.0000000000000074. Review.

30.

A kindred with fish eye disease, corneal opacities, marked high-density lipoprotein deficiency, and statin therapy.

Dimick SM, Sallee B, Asztalos BF, Pritchard PH, Frohlich J, Schaefer EJ.

J Clin Lipidol. 2014 Mar-Apr;8(2):223-30. doi: 10.1016/j.jacl.2013.11.005. Epub 2013 Dec 11.

PMID:
24636183
31.

The influence of apoE-deficiency and LDL-receptor-deficiency on the HDL subpopulation profile in mice and in humans.

Tani M, Matera R, Horvath KV, Hasan TS, Schaefer EJ, Asztalos BF.

Atherosclerosis. 2014 Mar;233(1):39-44. doi: 10.1016/j.atherosclerosis.2013.11.080. Epub 2013 Dec 31.

PMID:
24529120
32.

HDL deficiency due to a new insertion mutation (ApoA-INashua) and review of the literature.

Lee EY, Klementowicz PT, Hegele RA, Asztalos BF, Schaefer EJ.

J Clin Lipidol. 2013 Mar-Apr;7(2):169-73. doi: 10.1016/j.jacl.2012.10.011. Epub 2012 Nov 17. Review.

33.

A novel mutation in the ABCA1 gene causing an atypical phenotype of Tangier disease.

Negi SI, Brautbar A, Virani SS, Anand A, Polisecki E, Asztalos BF, Ballantyne CM, Schaefer EJ, Jones PH.

J Clin Lipidol. 2013 Jan-Feb;7(1):82-7. doi: 10.1016/j.jacl.2012.09.004. Epub 2012 Sep 29. Erratum in: J Clin Lipidol. 2013 Jul-Aug;7(4):385.

PMID:
23351586
34.

Effects of atorvastatin on human C-reactive protein metabolism.

Thongtang N, Diffenderfer MR, Ooi EM, Asztalos BF, Dolnikowski GG, Lamon-Fava S, Schaefer EJ.

Atherosclerosis. 2013 Feb;226(2):466-70. doi: 10.1016/j.atherosclerosis.2012.11.012. Epub 2012 Nov 23.

35.

Linkage between C-reactive protein and triglyceride-rich lipoprotein metabolism.

Thongtang N, Diffenderfer MR, Ooi EM, Asztalos BF, Dolnikowski GG, Lamon-Fava S, Schaefer EJ.

Metabolism. 2013 Mar;62(3):369-75. doi: 10.1016/j.metabol.2012.08.008. Epub 2012 Sep 25.

36.

Inflammation modulates human HDL composition and function in vivo.

de la Llera Moya M, McGillicuddy FC, Hinkle CC, Byrne M, Joshi MR, Nguyen V, Tabita-Martinez J, Wolfe ML, Badellino K, Pruscino L, Mehta NN, Asztalos BF, Reilly MP.

Atherosclerosis. 2012 Jun;222(2):390-4. doi: 10.1016/j.atherosclerosis.2012.02.032. Epub 2012 Feb 28.

37.

Homozygous lecithin:cholesterol acyltransferase (LCAT) deficiency due to a new loss of function mutation and review of the literature.

Roshan B, Ganda OP, Desilva R, Ganim RB, Ward E, Haessler SD, Polisecki EY, Asztalos BF, Schaefer EJ.

J Clin Lipidol. 2011 Nov-Dec;5(6):493-9. doi: 10.1016/j.jacl.2011.07.002. Epub 2011 Aug 23. Review.

38.

A sensitive assay for ABCA1-mediated cholesterol efflux using BODIPY-cholesterol.

Sankaranarayanan S, Kellner-Weibel G, de la Llera-Moya M, Phillips MC, Asztalos BF, Bittman R, Rothblat GH.

J Lipid Res. 2011 Dec;52(12):2332-40. doi: 10.1194/jlr.D018051. Epub 2011 Sep 27.

39.

Dysfunctional HDL containing L159R ApoA-I leads to exacerbation of atherosclerosis in hyperlipidemic mice.

Sorci-Thomas MG, Zabalawi M, Bharadwaj MS, Wilhelm AJ, Owen JS, Asztalos BF, Bhat S, Thomas MJ.

Biochim Biophys Acta. 2012 Mar;1821(3):502-12. doi: 10.1016/j.bbalip.2011.08.019. Epub 2011 Sep 14.

40.

Adiponectin: an independent risk factor for coronary heart disease in men in the Framingham offspring Study.

Ai M, Otokozawa S, Asztalos BF, White CC, Cupples LA, Nakajima K, Lamon-Fava S, Wilson PW, Matsuzawa Y, Schaefer EJ.

Atherosclerosis. 2011 Aug;217(2):543-8. doi: 10.1016/j.atherosclerosis.2011.05.035. Epub 2011 Jun 12.

41.

Metabolic and functional relevance of HDL subspecies.

Asztalos BF, Tani M, Schaefer EJ.

Curr Opin Lipidol. 2011 Jun;22(3):176-85. doi: 10.1097/MOL.0b013e3283468061. Review.

PMID:
21537175
42.

Protection from retinopathy and other complications in patients with type 1 diabetes of extreme duration: the joslin 50-year medalist study.

Sun JK, Keenan HA, Cavallerano JD, Asztalos BF, Schaefer EJ, Sell DR, Strauch CM, Monnier VM, Doria A, Aiello LP, King GL.

Diabetes Care. 2011 Apr;34(4):968-74. doi: 10.2337/dc10-1675.

43.

Effects of maximal atorvastatin and rosuvastatin treatment on markers of glucose homeostasis and inflammation.

Thongtang N, Ai M, Otokozawa S, Himbergen TV, Asztalos BF, Nakajima K, Stein E, Jones PH, Schaefer EJ.

Am J Cardiol. 2011 Feb 1;107(3):387-92. doi: 10.1016/j.amjcard.2010.09.031.

44.

High-density lipoprotein particles, coronary heart disease, and niacin.

Asztalos BF.

J Clin Lipidol. 2010 Sep-Oct;4(5):405-10. doi: 10.1016/j.jacl.2010.08.012. Epub 2010 Aug 19.

PMID:
21122684
45.

A case report of a diabetic woman with very low HDL cholesterol.

Chaychi L, Kinlaw WB, Asztalos BF, Schaefer EJ.

J Clin Lipidol. 2010 Mar-Apr;4(2):133-5. doi: 10.1016/j.jacl.2010.01.003. Epub 2010 Jan 29. No abstract available.

PMID:
21122641
46.

Direct assessment of plasma low density lipoprotein and high density lipoprotein cholesterol levels and coronary heart disease: results from the Framingham Offspring Study.

Otokozawa S, Ai M, Asztalos BF, White CC, Demissie-Banjaw S, Cupples LA, Nakajima K, Wilson PW, Schaefer EJ.

Atherosclerosis. 2010 Nov;213(1):251-5. doi: 10.1016/j.atherosclerosis.2010.02.041. Epub 2010 Mar 9.

47.

Importance of macrophage cholesterol content on the flux of cholesterol mass.

Sankaranarayanan S, de la Llera-Moya M, Drazul-Schrader D, Asztalos BF, Weibel GL, Rothblat GH.

J Lipid Res. 2010 Nov;51(11):3243-9. doi: 10.1194/jlr.M008441. Epub 2010 Aug 16.

48.

Effects of weight loss, induced by gastric bypass surgery, on HDL remodeling in obese women.

Asztalos BF, Swarbrick MM, Schaefer EJ, Dallal GE, Horvath KV, Ai M, Stanhope KL, Austrheim-Smith I, Wolfe BM, Ali M, Havel PJ.

J Lipid Res. 2010 Aug;51(8):2405-12. doi: 10.1194/jlr.P900015.

49.

Circulating Nef induces dyslipidemia in simian immunodeficiency virus-infected macaques by suppressing cholesterol efflux.

Asztalos BF, Mujawar Z, Morrow MP, Grant A, Pushkarsky T, Wanke C, Shannon R, Geyer M, Kirchhoff F, Sviridov D, Fitzgerald ML, Bukrinsky M, Mansfield KG.

J Infect Dis. 2010 Aug 15;202(4):614-23. doi: 10.1086/654817.

50.

Marked HDL deficiency and premature coronary heart disease.

Schaefer EJ, Santos RD, Asztalos BF.

Curr Opin Lipidol. 2010 Aug;21(4):289-97. doi: 10.1097/MOL.0b013e32833c1ef6. Review.

PMID:
20616715

Supplemental Content

Loading ...
Support Center